Due to these challenges, there has yet to be an anti-TGF-β therapy that has successfully found the balance between achieving an adequate anti-fibrotic response whilst avoiding serious cardiovascular side effects, despite candidate drugs such as galunisertib showing initial promise in cancer trials56,57. This evidence concerns the gene TGFB1 and cancer.